Head and Neck Cancer

HEAD AND NECK CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

RB-RECIST Criteria May Improve Retinoblastoma Management: An Interview With Jesse L. Berry, MD

In an international, multicenter collaboration, experts modified the RECIST criteria for use as objective endpoints in clinical trials of retinoblastoma therapies.
COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.
NCI-MATCH Trial Identifies Actionable Alterations in More Than One-Third of Patients With Cancer

Researchers have identified actionable alterations in nearly 38% of patients with cancer, and almost 18% of patients were assigned to treatments based on their molecular profiling results.

HEAD AND NECK CANCER NEWS

Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of

Endoscopic Surgery Improved OS for Locally Recurrent Nasopharyngeal Cancer

March 31, 2021

The ACS identified 5 key areas for long-term clinical care of survivors of head and neck cancer, a g

KESTREL Trial Testing Durvalumab With or Without Tremelimumab in HNSCC Misses OS End Points

February 23, 2021

Identifying Molecular Subtypes of Head and Neck Cancer May Lead to Effective Preventive Treatment

Study Establishes Feasibility of Reduced-Dose IMRT Plus Cisplatin in Good-Risk HPV-Associated OPSCC

February 9, 2021

Patients with anemia had worse in-hospital outcomes.

Symptom Assessment Scores Associated With Unplanned Hospitalizations in Patients With Head and Neck Cancer

February 1, 2021

A doctor speaks with an old, white patient.

Prolonged-Duration Chemoprophylaxis Decreased VTE in Patients Undergoing Surgery for Head and Neck Cancer

January 27, 2021

Next post in Head and Neck Cancer

The ACS identified 5 key areas for long-term clinical care of survivors of head and neck cancer, a g

KESTREL Trial Testing Durvalumab With or Without Tremelimumab in HNSCC Misses OS End Points